Curated News
By: NewsRamp Editorial Staff
August 17, 2026
LCFA and IASLC Award $200K to Young Lung Cancer Researchers
TLDR
- LCFA and IASLC award $200,000 to two early-career researchers, giving them a competitive edge to secure major funding and advance lung cancer breakthroughs.
- The Early Career Researcher grant program provides seed funding with a 13X multiplier effect, converting $4.6 million into over $50 million in follow-on grants.
- Investing in young scientists accelerates lung cancer research, aiming to catch the disease earlier and overcome treatment resistance, ultimately helping patients live longer, better lives.
- Did you know lung cancer claims a life every 4.2 minutes in the US, yet two scientists are now funded to explore lung bacteria's role and cancer's energy use.
Impact - Why it Matters
This funding is crucial because it empowers emerging scientists to pursue high-risk, high-reward research that often lacks traditional funding. By supporting these early-career investigators, LCFA and IASLC are not only advancing lung cancer science but also ensuring that the next generation of breakthroughs can happen. The ripple effect of this investment extends far beyond the initial grants, as it has historically led to millions in additional funding, ultimately accelerating the development of new treatments and diagnostic tools that could save lives. For patients and families affected by lung cancer, this means hope for earlier detection and more effective therapies in the future.
Summary
In observance of World Lung Cancer Day, the Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) are awarding $200,000 to two promising early-career scientists, Dr. Jared Mayers of Fred Hutch Cancer Center and Dr. Jaime L. Schneider of Dana-Farber Cancer Institute. These grants, part of the Early Career Researcher (ECR) grant program, aim to address the critical lack of resources that often stalls innovative research. The funding will support Dr. Mayers' investigation into lung microbiome's role in cancer development and Dr. Schneider's work on overcoming drug resistance in lung cancer. Both projects target early detection and treatment hurdles, with the goal of improving patient outcomes.
LCFA and IASLC emphasize the urgency of this investment, noting that lung cancer claims a life every 4.2 minutes in the U.S. The ECR program has a proven "multiplier effect," with a 13X return on investment, having turned $4.6 million in grants into over $50 million in subsequent funding. Kim Norris, LCFA co-founder and president, underscores that supporting early-career investigators is essential for the future of oncology. The recipients, selected for their innovative proposals, will gain momentum to translate their ideas into clinical applications. For more insights, visit LCFA's Meet the Researcher page. This $400,000 investment underscores both organizations' commitment to accelerating discovery for patients worldwide.
Source Statement
This curated news summary relied on content distributed by NewsUSA. Read the original source here, LCFA and IASLC Award $200K to Young Lung Cancer Researchers
